Less Is More?: Bioresorbable Vascular Scaffold vs Drug-Eluting Metallic Stent: 10-Year Follow-Up

ABSORB bioresorbable vascular scaffold (BVS) emerged in 2012 aiming to provide early mechanical support while restoring normal vascular function after its complete resorption. Subsequent trials raised safety concerns over early higher scaffold thrombosis rates compared with metallic drug-eluting stent (DES). However, very long-term outcomes of BVS remain insufficiently reported.

A 71-year-old man presenting with stable angina had both BVS and DES implanted in the same vessel in 2014. Restudy angiogram and intravascular optical coherence tomography showed satisfactory outcome of both stents 10 years later.

This case illustrated patient and lesion selection, proper sizing, predilatation, and postdilatation contributed to successful long-term outcome of BVS.

This case demonstrated satisfactory 10-year outcome of BVS that is comparable with DES in the same vessel of the same patient. The patient and lesion selection, proper sizing, predilatation, and postdilatation implantation techniques are the keys to satisfactory long-term outcome of BVS.